We are live on ! Find out more
AIMT

Aimmune Therapeutics
AIMT

Delisted

AIMT was delisted on the 12th of October, 2020.

Back to rankings

58 hedge funds and large institutions have $551M invested in Aimmune Therapeutics in 2015 Q3 according to their latest regulatory filings, with 58 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
58
Holders Change
+58
Holders Change %
–
% of All Funds
1.62%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.06%
New
58
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$142M
2
FCMI
Foresite Capital Management II
California
+$95.6M
3
AC
Aisling Capital
New York
+$65.9M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$29M
5
PHS
PFM Health Sciences
California
+$23.3M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$154M +$142M +6,087,235 New
FCMI
2
Foresite Capital Management II
California
$104M +$95.6M +4,087,900 New
AC
3
Aisling Capital
New York
$71.4M +$65.9M +2,820,000 New
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$31.4M +$29M +1,241,400 New
PHS
5
PFM Health Sciences
California
$25.2M +$23.3M +996,112 New
SAM
6
Sectoral Asset Management
Quebec, Canada
$20.1M +$18.5M +792,638 New
RCM
7
RA Capital Management
Massachusetts
$20M +$18.5M +790,200 New
RIM
8
RS Investment Management
California
$18.1M +$16.7M +715,963 New
AllianceBernstein
9
AllianceBernstein
Tennessee
$15.3M +$14.2M +606,029 New
Vanguard Group
10
Vanguard Group
Pennsylvania
$14.3M +$13.2M +562,924 New
T. Rowe Price Associates
11
T. Rowe Price Associates
Maryland
$11.2M +$10.3M +441,638 New
PAI
12
Palo Alto Investors
California
$8.24M +$7.61M +325,599 New
BFA
13
BlackRock Fund Advisors
California
$6.73M +$6.21M +265,713 New
BBA
14
Baker Bros. Advisors
New York
$6.33M +$5.84M +250,000 New
Jennison Associates
15
Jennison Associates
New York
$5.08M +$4.69M +200,503 New
RSCM
16
Rock Springs Capital Management
Maryland
$5.06M +$4.68M +200,000 New
FAM
17
Fred Alger Management
New York
$3.75M +$3.47M +148,299 New
State Street
18
State Street
Massachusetts
$3.08M +$2.84M +121,537 New
BIT
19
BlackRock Institutional Trust
California
$2.63M +$2.43M +103,915 New
American Century Companies
20
American Century Companies
Missouri
$2.08M +$1.92M +82,292 New
PAMU
21
Pictet Asset Management (UK)
United Kingdom
$1.94M +$1.79M +76,600 New
Franklin Resources
22
Franklin Resources
California
$1.73M +$1.6M +68,413 New
Geode Capital Management
23
Geode Capital Management
Massachusetts
$1.69M +$1.56M +66,746 New
CS
24
Credit Suisse
Switzerland
$1.67M +$1.54M +65,924 New
DCM
25
Driehaus Capital Management
Illinois
$1.63M +$1.5M +64,315 New
1
2 3

AIMT Hedge Fund Activity: Q3 2015 in Review

58 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q3 2015, worth a combined $551M.

Buyers outnumbered sellers: 58 funds opened new AIMT positions and 0 closed out — a net gain of 58 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $142M.

  • 58 institutional investors held Aimmune Therapeutics (AIMT) as of Q3 2015, up from 0 in Q2 2015.
  • Funds reported $551M of Aimmune Therapeutics stock for Q3 2015.
  • 58 funds opened new Aimmune Therapeutics positions in Q3 2015 and 0 closed out, a net change of +58 holders.
  • The largest Aimmune Therapeutics buyer in Q3 2015 was Fidelity Investments, an estimated $142M added.

Based on aggregated 13F filings for Q3 2015.